Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.86
SKBI's Cash to Debt is ranked higher than
66% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.20 vs. SKBI: 0.86 )
SKBI' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 0.86

Equity to Asset 0.73
SKBI's Equity to Asset is ranked higher than
81% of the 754 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. SKBI: 0.73 )
SKBI' s 10-Year Equity to Asset Range
Min: -1563   Max: 0.91
Current: 0.73

-1563
0.91
Interest Coverage 21.26
SKBI's Interest Coverage is ranked higher than
61% of the 488 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 101.25 vs. SKBI: 21.26 )
SKBI' s 10-Year Interest Coverage Range
Min: 1   Max: 9999.99
Current: 21.26

1
9999.99
F-Score: 6
Z-Score: 2.08
M-Score: -2.11
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 25.57
SKBI's Operating margin (%) is ranked higher than
95% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.92 vs. SKBI: 25.57 )
SKBI' s 10-Year Operating margin (%) Range
Min: -50916.67   Max: 38.08
Current: 25.57

-50916.67
38.08
Net-margin (%) 21.10
SKBI's Net-margin (%) is ranked higher than
95% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.26 vs. SKBI: 21.10 )
SKBI' s 10-Year Net-margin (%) Range
Min: -75166.67   Max: 29.63
Current: 21.1

-75166.67
29.63
ROE (%) 9.05
SKBI's ROE (%) is ranked higher than
79% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.33 vs. SKBI: 9.05 )
SKBI' s 10-Year ROE (%) Range
Min: -56375   Max: 80.86
Current: 9.05

-56375
80.86
ROA (%) 7.15
SKBI's ROA (%) is ranked higher than
84% of the 814 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.07 vs. SKBI: 7.15 )
SKBI' s 10-Year ROA (%) Range
Min: -60200   Max: 37.93
Current: 7.15

-60200
37.93
ROC (Joel Greenblatt) (%) 11.63
SKBI's ROC (Joel Greenblatt) (%) is ranked higher than
73% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.20 vs. SKBI: 11.63 )
SKBI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6431.58   Max: 105.87
Current: 11.63

-6431.58
105.87
Revenue Growth (%) -5.90
SKBI's Revenue Growth (%) is ranked higher than
55% of the 655 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. SKBI: -5.90 )
SKBI' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 44.4
Current: -5.9

0
44.4
EBITDA Growth (%) -8.80
SKBI's EBITDA Growth (%) is ranked higher than
60% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. SKBI: -8.80 )
SKBI' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 78.9
Current: -8.8

0
78.9
EPS Growth (%) -11.20
SKBI's EPS Growth (%) is ranked higher than
64% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. SKBI: -11.20 )
SKBI' s 10-Year EPS Growth (%) Range
Min: 0   Max: 53.3
Current: -11.2

0
53.3
» SKBI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with SKBI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 3.30
SKBI's P/E(ttm) is ranked higher than
100% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 41.30 vs. SKBI: 3.30 )
SKBI' s 10-Year P/E(ttm) Range
Min: 0.78   Max: 486.49
Current: 3.3

0.78
486.49
P/B 0.28
SKBI's P/B is ranked higher than
99% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.39 vs. SKBI: 0.28 )
SKBI' s 10-Year P/B Range
Min: 0.09   Max: 7.87
Current: 0.28

0.09
7.87
P/S 0.69
SKBI's P/S is ranked higher than
95% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.81 vs. SKBI: 0.69 )
SKBI' s 10-Year P/S Range
Min: 0.22   Max: 12.58
Current: 0.69

0.22
12.58
PFCF 2.17
SKBI's PFCF is ranked higher than
100% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. SKBI: 2.17 )
SKBI' s 10-Year PFCF Range
Min: 1.96   Max: 193.75
Current: 2.17

1.96
193.75
EV-to-EBIT 3.15
SKBI's EV-to-EBIT is ranked higher than
99% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 30.17 vs. SKBI: 3.15 )
SKBI' s 10-Year EV-to-EBIT Range
Min: 0.6   Max: 44.6
Current: 3.15

0.6
44.6
Shiller P/E 2.53
SKBI's Shiller P/E is ranked higher than
99% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 101.28 vs. SKBI: 2.53 )
SKBI' s 10-Year Shiller P/E Range
Min: 0.94   Max: 1090
Current: 2.53

0.94
1090
Current Ratio 2.53
SKBI's Current Ratio is ranked higher than
73% of the 809 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.28 vs. SKBI: 2.53 )
SKBI' s 10-Year Current Ratio Range
Min: 0.01   Max: 9.57
Current: 2.53

0.01
9.57
Quick Ratio 1.97
SKBI's Quick Ratio is ranked higher than
75% of the 809 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. SKBI: 1.97 )
SKBI' s 10-Year Quick Ratio Range
Min: 0.01   Max: 7.56
Current: 1.97

0.01
7.56

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 0.29
SKBI's Price/Tangible Book is ranked higher than
99% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. SKBI: 0.29 )
SKBI' s 10-Year Price/Tangible Book Range
Min: 0.1   Max: 47.62
Current: 0.29

0.1
47.62
Price/DCF (Projected) 0.33
SKBI's Price/DCF (Projected) is ranked higher than
99% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.11 vs. SKBI: 0.33 )
SKBI' s 10-Year Price/DCF (Projected) Range
Min: 0.15   Max: 23.46
Current: 0.33

0.15
23.46
Price/Median PS Value 0.51
SKBI's Price/Median PS Value is ranked higher than
97% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.27 vs. SKBI: 0.51 )
SKBI' s 10-Year Price/Median PS Value Range
Min: 0.19   Max: 54.32
Current: 0.51

0.19
54.32
Price/Graham Number 0.21
SKBI's Price/Graham Number is ranked higher than
100% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.82 vs. SKBI: 0.21 )
SKBI' s 10-Year Price/Graham Number Range
Min: 0.08   Max: 17.7
Current: 0.21

0.08
17.7
Earnings Yield (Greenblatt) 31.70
SKBI's Earnings Yield (Greenblatt) is ranked higher than
98% of the 665 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.90 vs. SKBI: 31.70 )
SKBI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.2   Max: 157
Current: 31.7

2.2
157
Forward Rate of Return (Yacktman) -10.92
SKBI's Forward Rate of Return (Yacktman) is ranked higher than
57% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.05 vs. SKBI: -10.92 )
SKBI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -396.9   Max: 12.2
Current: -10.92

-396.9
12.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:GNJC.Germany
Skystar Bio-Pharmaceutical Company was incorporated in Nevada on September 24, 1998. Since its acquisition on November 7, 2005 of Skystar Bio-Pharmaceutical Holdings Co., Ltd., a Cayman Islands company, it has been engaged in the research, development, production, marketing, and sales of veterinary healthcare and medical care products. All current operations of the company are in the People's Republic of China. All of the company's operations are carried out by Xi'an Tianxing Bio-Pharmaceutical Co., Limited, a PRC joint stock company that it controls through contractual arrangements originally between Skystar Cayman and Xi'an Tianxing. The Company has four major product line micro-organism products line; veterinary medicine line; feed additives line; bio-pharmaceutical veterinary vaccine line. Its micro-organism products line includes over 16 products; veterinary medicine line for poultry and livestock includes over 245 products; feed additives line includes over 16 products; and its bio-pharmaceutical veterinary vaccine line includes over 10 products. As of December 31, 2012, the company had over 3,964 customers in 29 provinces in China, including 2,859 distributors and 1,105 direct customers. Of the 2,859 distributors, 360 are physical stores that have outer signage with its logo and sell products from its four product lines exclusively that are known as 'franchise distributors.' The Company is able to compete with the competitors due to its quick response to market demand, product offerings, quality customer service, and competitive prices.
» More Articles for NAS:SKBI

Headlines

Articles On GuruFocus.com
animal vaccination w Oct 11 2011 

More From Other Websites
Skystar Bio-Pharmaceutical (SKBI) Upgraded From Hold to Buy Sep 09 2014
Skystar to Launch Probiotic Supplement for Dairy Cows by End of Fiscal 2014 Aug 26 2014
SKYSTAR BIO-PHARMACEUTICAL CO Financials Aug 22 2014
Skystar Bio-Pharmaceutical Reports Second Quarter Fiscal Year 2014 Financial Results Aug 14 2014
Skystar Bio-Pharmaceutical to File Financial Results for Second Quarter of Fiscal 2014 on Thursday,... Aug 14 2014
SKYSTAR BIO-PHARMACEUTICAL CO Files SEC form 10-Q, Quarterly Report Aug 14 2014
SKYSTAR BIO-PHARMACEUTICAL CO Files SEC form 8-K, Material Modification to Rights of Security... Jul 21 2014
SKYSTAR BIO-PHARMACEUTICAL CO Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jul 16 2014
Skystar Bio-Pharmaceutical Announces $5 Million Registered Direct Offering Jul 16 2014
Skystar Bio-Pharma launches bovine immunoglobulin G kits in China Jul 08 2014
Skystar Launches Bovine Immunoglobulin G (IgG) Kits in China Jul 08 2014
Skystar Bio-Pharmaceutical's (SKBI) CEO Weibing Lu on Q1 2014 Results - Earnings Call Transcript May 16 2014
Skystar Bio-Pharmaceutical Reports First Quarter Fiscal Year 2014 Financial Results May 15 2014
SKYSTAR BIO-PHARMACEUTICAL CO Files SEC form 10-Q, Quarterly Report May 15 2014
Skystar Bio-Pharmaceutical to File Financial Results for First Quarter of Fiscal 2014 on Thursday,... May 15 2014
Skystar Bio-Pharmaceutical Provides Update to Its Patent Portfolio Apr 17 2014
SKYSTAR BIO-PHARMACEUTICAL CO Files SEC form 8-K, Other Events Apr 16 2014
Skystar Bio Pharmaceutical Company: Undervalued With A Strong Growth Catalyst Apr 15 2014
Skystar Bio-Pharmaceutical's Management Discusses Q4 2013 Results - Earnings Call Transcript Apr 01 2014
Skystar Bio-Pharmaceutical Reports Fiscal Year 2013 Financial Results and Meets Full Year Guidance Mar 31 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK